Patents by Inventor Henry Bennett
Henry Bennett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180064381Abstract: Optical coherence tomography (herein “OCT”) based analyte monitoring systems are disclosed. In one aspect, techniques are disclosed that can identify fluid flow in vivo (e.g., blood flow), which can act as a metric for gauging the extent of blood perfusion in tissue. For instance, if OCT is to be used to estimate the level of an analyte (e.g., glucose) in tissue, a measure of the extent of blood flow can potentially indicate the presence of an analyte correlating region, which would be suitable for analyte level estimation with OCT. Another aspect is related to systems and methods for scanning multiple regions. An optical beam is moved across the surface of the tissue in two distinct manners. The first can be a coarse scan, moving the beam to provide distinct scanning positions on the skin. The second can be a fine scan where the beam is applied for more detailed analysis.Type: ApplicationFiled: October 31, 2017Publication date: March 8, 2018Inventors: Walter J. Shakespeare, William Henry Bennett, Jason T. Iceman, Howard P. Apple, Phillip William Wallace, Matthew J. Schurman
-
Patent number: 9833180Abstract: Optical coherence tomography (herein “OCT”) based analyte monitoring systems are disclosed. In one aspect, techniques are disclosed that can identify fluid flow in vivo (e.g., blood flow), which can act as a metric for gauging the extent of blood perfusion in tissue. For instance, if OCT is to be used to estimate the level of an analyte (e.g., glucose) in tissue, a measure of the extent of blood flow can potentially indicate the presence of an analyte correlating region, which would be suitable for analyte level estimation with OCT. Another aspect is related to systems and methods for scanning multiple regions. An optical beam is moved across the surface of the tissue in two distinct manners. The first can be a coarse scan, moving the beam to provide distinct scanning positions on the skin. The second can be a fine scan where the beam is applied for more detailed analysis.Type: GrantFiled: May 16, 2014Date of Patent: December 5, 2017Assignee: MASIMO CORPORATIONInventors: Walter J. Shakespeare, William Henry Bennett, Jason T. Iceman, Howard P. Apple, Phillip William Wallace, Matthew J. Schurman
-
Publication number: 20170311851Abstract: The present invention relates to a method and system for estimating blood analyte levels using a noninvasive optical coherence tomography (OCT) based physiological monitor. An algorithm correlates OCT-based estimated blood analyte data with actual blood analyte data determined by other methods, such as invasively. OCT-based data is fit to the obtained blood analyte measurements to achieve the best correlation. Once the algorithm has generated sets of estimated blood analyte levels, it may refine the number of sets by applying one or more mathematical filters. The OCT-based physiological monitor can be calibrated using an Intensity Difference plot or the Pearson Product Moment Correlation method.Type: ApplicationFiled: May 25, 2017Publication date: November 2, 2017Inventors: Matthew J. Schurman, Walter J. Shakespeare, William Henry Bennett
-
Patent number: 9554737Abstract: A method for noninvasively measuring analyte levels includes using a non-imaging OCT-based system to scan a two-dimensional area of biological tissue and gather data continuously during the scanning. Structures within the tissue where measured-analyte-induced changes to the OCT data dominate over changes induced by other analytes are identified by focusing on highly localized regions of the data curve produced from the OCT scan which correspond to discontinuities in the OCT data curve. The data from these localized regions then can be related to measured analyte levels.Type: GrantFiled: September 25, 2013Date of Patent: January 31, 2017Assignee: MASIMO CORPORATIONInventors: Matthew J. Schurman, Walter J. Shakespeare, William Henry Bennett
-
Patent number: 9078560Abstract: The present invention relates to a method and system for estimating blood analyte levels using a noninvasive optical coherence tomography (OCT) based physiological monitor. An algorithm correlates OCT-based estimated blood analyte data with actual blood analyte data determined by other methods, such as invasively. OCT-based data is fit to the obtained blood analyte measurements to achieve the best correlation. Once the algorithm has generated sets of estimated blood analyte levels, it may refine the number of sets by applying one or more mathematical filters. The OCT-based physiological monitor can be calibrated using an Intensity Difference plot or the Pearson Product Moment Correlation method.Type: GrantFiled: November 2, 2012Date of Patent: July 14, 2015Assignee: GLT ACQUISITION CORP.Inventors: Matthew J. Schurman, Walter J. Shakespeare, William Henry Bennett
-
Publication number: 20150126830Abstract: A system and a method for creating a stable and reproducible interface of an optical sensor system for measuring blood glucose levels in biological tissue include a dual wedge prism sensor attached to a disposable optic that comprises a focusing lens and an optical window. The disposable optic adheres to the skin to allow a patient to take multiple readings or scans at the same location. The disposable optic includes a Petzval surface placed flush against the skin to maintain the focal point of the optical beam on the surface of the skin. Additionally, the integrity of the sensor signal is maximized by varying the rotation rates of the dual wedge prisms over time in relation to the depth scan rate of the sensor. Optimally, a medium may be injected between the disposable and the skin to match the respective refractive indices and optimize the signal collection of the sensor.Type: ApplicationFiled: August 4, 2014Publication date: May 7, 2015Inventors: Matthew J. Schurman, Phillip William Wallace, Walter J. Shakespeare, Howard P. Apple, William Henry Bennett
-
Publication number: 20140336481Abstract: Optical coherence tomography (herein “OCT”) based analyte monitoring systems are disclosed. In one aspect, techniques are disclosed that can identify fluid flow in vivo (e.g., blood flow), which can act as a metric for gauging the extent of blood perfusion in tissue. For instance, if OCT is to be used to estimate the level of an analyte (e.g., glucose) in tissue, a measure of the extent of blood flow can potentially indicate the presence of an analyte correlating region, which would be suitable for analyte level estimation with OCT. Another aspect is related to systems and methods for scanning multiple regions. An optical beam is moved across the surface of the tissue in two distinct manners. The first can be a coarse scan, moving the beam to provide distinct scanning positions on the skin. The second can be a fine scan where the beam is applied for more detailed analysis.Type: ApplicationFiled: May 16, 2014Publication date: November 13, 2014Applicant: GLT ACQUISITION CORP.Inventors: Walter J. Shakespeare, William Henry Bennett, Jason T. Iceman, Howard P. Apple, Phillip William Wallace, Matthew J. Schurman
-
Patent number: 8831700Abstract: A system and a method for creating a stable and reproducible interface of an optical sensor system for measuring blood glucose levels in biological tissue include a dual wedge prism sensor attached to a disposable optic that comprises a focusing lens and an optical window. The disposable optic adheres to the skin to allow a patient to take multiple readings or scans at the same location. The disposable optic includes a Petzval surface placed flush against the skin to maintain the focal point of the optical beam on the surface of the skin. Additionally, the integrity of the sensor signal is maximized by varying the rotation rates of the dual wedge prisms over time in relation to the depth scan rate of the sensor. Optimally, a medium may be injected between the disposable and the skin to match the respective refractive indices and optimize the signal collection of the sensor.Type: GrantFiled: July 9, 2012Date of Patent: September 9, 2014Assignee: GLT Acquisition Corp.Inventors: Matthew J. Schurman, Phillip William Wallace, Walter J. Shakespeare, Howard P. Apple, William Henry Bennett
-
Patent number: 8768423Abstract: Optical coherence tomography (herein “OCT”) based analyte monitoring systems are disclosed. In one aspect, techniques are disclosed that can identify fluid flow in vivo (e.g., blood flow), which can act as a metric for gauging the extent of blood perfusion in tissue. For instance, if OCT is to be used to estimate the level of an analyte (e.g., glucose) in tissue, a measure of the extent of blood flow can potentially indicate the presence of an analyte correlating region, which would be suitable for analyte level estimation with OCT. Another aspect is related to systems and methods for scanning multiple regions. An optical beam is moved across the surface of the tissue in two distinct manners. The first can be a coarse scan, moving the beam to provide distinct scanning positions on the skin. The second can be a fine scan where the beam is applied for more detailed analysis.Type: GrantFiled: March 4, 2009Date of Patent: July 1, 2014Assignee: GLT Acquisition Corp.Inventors: Walter J. Shakespeare, William Henry Bennett, Jason T. Iceman, Howard P. Apple, Phillip William Wallace, Matthew J. Schurman
-
Publication number: 20140094667Abstract: A method for noninvasively measuring analyte levels includes using a non-imaging OCT-based system to scan a two-dimensional area of biological tissue and gather data continuously during the scanning. Structures within the tissue where measured-analyte-induced changes to the OCT data dominate over changes induced by other analytes are identified by focusing on highly localized regions of the data curve produced from the OCT scan which correspond to discontinuities in the OCT data curve. The data from these localized regions then can be related to measured analyte levels.Type: ApplicationFiled: September 25, 2013Publication date: April 3, 2014Applicant: GLT Acquisition CorporationInventors: Matthew J. Schurman, Walter J. Shakespeare, William Henry Bennett
-
Patent number: 8548549Abstract: A method for noninvasively measuring analyte levels includes using a non-imaging OCT-based system to scan a two-dimensional area of biological tissue and gather data continuously during the scanning. Structures within the tissue where measured-analyte-induced changes to the OCT data dominate over changes induced by other analytes are identified by focusing on highly localized regions of the data curve produced from the OCT scan which correspond to discontinuities in the OCT data curve. The data from these localized regions then can be related to measured analyte levels.Type: GrantFiled: September 9, 2011Date of Patent: October 1, 2013Assignee: GLT Acquisition Corp.Inventors: Matthew J. Schurman, Walter J. Shakespeare, William Henry Bennett
-
Patent number: 8306596Abstract: The present invention relates to a method and system for estimating blood analyte levels using a noninvasive optical coherence tomography (OCT) based physiological monitor. An algorithm correlates OCT-based estimated blood analyte data with actual blood analyte data determined by other methods, such as invasively. OCT-based data is fit to the obtained blood analyte measurements to achieve the best correlation. Once the algorithm has generated sets of estimated blood analyte levels, it may refine the number of sets by applying one or more mathematical filters. The OCT-based physiological monitor can be calibrated using an Intensity Difference plot or the Pearson Product Moment Correlation method.Type: GrantFiled: September 22, 2010Date of Patent: November 6, 2012Assignee: GLT Acquisition Corp.Inventors: Matthew J. Schurman, Walter J. Shakespeare, William Henry Bennett
-
Publication number: 20120277554Abstract: A system and a method for creating a stable and reproducible interface of an optical sensor system for measuring blood glucose levels in biological tissue include a dual wedge prism sensor attached to a disposable optic that comprises a focusing lens and an optical window. The disposable optic adheres to the skin to allow a patient to take multiple readings or scans at the same location. The disposable optic includes a Petzval surface placed flush against the skin to maintain the focal point of the optical beam on the surface of the skin. Additionally, the integrity of the sensor signal is maximized by varying the rotation rates of the dual wedge prisms over time in relation to the depth scan rate of the sensor. Optimally, a medium may be injected between the disposable and the skin to match the respective refractive indices and optimize the signal collection of the sensor.Type: ApplicationFiled: July 9, 2012Publication date: November 1, 2012Applicant: GLT ACQUISITION CORP.Inventors: Matthew J. Schurman, Phillip William Wallace, Walter J. Shakespeare, Howard P. Apple, William Henry Bennett
-
Patent number: 8219172Abstract: A system and a method for creating a stable and reproducible interface of an optical sensor system for measuring blood glucose levels in biological tissue include a dual wedge prism sensor attached to a disposable optic that comprises a focusing lens and an optical window. The disposable optic adheres to the skin to allow a patient to take multiple readings or scans at the same location. The disposable optic includes a Petzval surface placed flush against the skin to maintain the focal point of the optical beam on the surface of the skin. Additionally, the integrity of the sensor signal is maximized by varying the rotation rates of the dual wedge prisms over time in relation to the depth scan rate of the sensor. Optimally, a medium may be injected between the disposable and the skin to match the respective refractive indices and optimize the signal collection of the sensor.Type: GrantFiled: March 17, 2006Date of Patent: July 10, 2012Assignee: GLT Acquisition Corp.Inventors: Matthew J. Schurman, Phillip William Wallace, Walter J. Shakespeare, Howard P. Apple, William Henry Bennett
-
Publication number: 20110319731Abstract: A method for noninvasively measuring analytes such as blood glucose levels includes using a non-imaging OCT-based system to scan a two-dimensional area of biological tissue and gather data continuously during the scanning. Structures within the tissue where measured-analyte-induced changes to the OCT data dominate over changes induced by other analytes are identified by focusing on highly localized regions of the data curve produced from the OCT scan which correspond to discontinuities in the OCT data curve. The data from these localized regions then can be related to measured analyte levels.Type: ApplicationFiled: September 9, 2011Publication date: December 29, 2011Applicant: GLT ACQUISITION CORP.Inventors: Matthew J. Schurman, Walter J. Shakespeare, William Henry Bennett
-
Patent number: 8036727Abstract: A method for noninvasively measuring analytes such as blood glucose levels includes using a non-imaging OCT-based system to scan a two-dimensional area of biological tissue and gather data continuously during the scanning. Structures within the tissue where measured-analyte-induced changes to the OCT data dominate over changes induced by other analytes are identified by focusing on highly localized regions of the data curve produced from the OCT scan which correspond to discontinuities in the OCT data curve. The data from these localized regions then can be related to measured analyte levels.Type: GrantFiled: June 2, 2006Date of Patent: October 11, 2011Assignee: GLT Acquisition Corp.Inventors: Matthew J. Schurman, Walter J. Shakespeare, William Henry Bennett
-
Patent number: 7822452Abstract: The present invention relates to a method for estimating blood glucose levels using a noninvasive optical coherence tomography- (OCT-) based blood glucose monitor. An algorithm correlates OCT-based estimated blood glucose data with actual blood glucose data determined by invasive methods. OCT-based data is fit to the obtained blood glucose measurements to achieve the best correlation. Once the algorithm has generated sets of estimated blood glucose levels, it may refine the number of sets by applying one or more mathematical filters. The OCT-based blood glucose monitor is calibrated using an Intensity Difference plot or the Pearson Product Moment Correlation method.Type: GrantFiled: April 13, 2006Date of Patent: October 26, 2010Assignee: GLT Acquisition Corp.Inventors: Matthew J. Schurman, Walter J. Shakespeare, William Henry Bennett
-
Publication number: 20100113900Abstract: Optical coherence tomography (herein “OCT”) based analyte monitoring systems are disclosed. In one aspect, techniques are disclosed that can identify fluid flow in vivo (e.g., blood flow), which can act as a metric for gauging the extent of blood perfusion in tissue. For instance, if OCT is to be used to estimate the level of an analyte (e.g., glucose) in tissue, a measure of the extent of blood flow can potentially indicate the presence of an analyte correlating region, which would be suitable for analyte level estimation with OCT. Another aspect is related to systems and methods for scanning multiple regions. An optical beam is moved across the surface of the tissue in two distinct manners. The first can be a coarse scan, moving the beam to provide distinct scanning positions on the skin. The second can be a fine scan where the beam is applied for more detailed analysis.Type: ApplicationFiled: March 4, 2009Publication date: May 6, 2010Applicant: GlucoLight CorporationInventors: Walter J. Shakespeare, William Henry Bennett, Jason T. Iceman, Howard P. Apple, Phillip William Wallace, Matthew J. Schurman
-
Patent number: 5764769Abstract: An apparatus and method produce a videotape or other recording that cannot be pre- or post-dated, nor altered, nor easily fabricated by electronically combining pre-recorded material. In order to prevent such falsification, the camera or other recording apparatus periodically receives certifiably unpredictable signals ("challenges") from a trusted source, causes these signals to influence the scene being recorded, then periodically forwards a digest of the ongoing digital recording to a trusted repository. The unpredictable challenges prevent pre-dating of the recording before the time of the challenge, while the storage of a digest prevents post-dating of the recording after the time the digest was received by the repository.Type: GrantFiled: July 31, 1996Date of Patent: June 9, 1998Assignee: International Business Machines CorporationInventors: Charles Henry Bennett, David Peter DiVincenzo, Ralph Linsker
-
Patent number: 5680455Abstract: A method and apparatus authenticates and provides non-reputability for analog messages which renders it impossible for a person, including the recipient, who is not in possession of a (cryptographic) key belonging to the claimed sender, to forge the message. The recipient is able to verify that the sender possessed the correct key, and a third party (judge) can establish whether the message was forged or not. This is accomplished by interposing a digital signature generator/verifier/recorder (DS-GVR) module in the sending apparatus, such as a facsimile machine. The receiver, using another DS-GVR, can verify that a received document comes from the purported sender and has not been altered enroute. The receiver's DS-GVR module can be made to produce a machine-readable record of the signed transmission.Type: GrantFiled: July 10, 1996Date of Patent: October 21, 1997Assignee: International Business Machines CorporationInventors: Ralph Linsker, Charles Henry Bennett